Table 3.
Therapies and Outcomes of the Enrolled Patients
| Variables | Total n=60 | Asthmatic (COVID-19 +) n=10 (16.7%) | Asthmatic (COVID-19 –) n=50 (83.3%) | P value |
|---|---|---|---|---|
| Management, No (%) | ||||
| Systemic steroids | 60 (100%) | 10 (100%) | 50(100%) | – |
| Bronchodilators (SABA) | 60 (100%) | 10 (100%) | 50(100%) | – |
| Critical care admission and respiratory support, No (%) | ||||
| PICU admission | 14 (23.3%) | 3 (30%) | 12 (24%) | 0.699 |
| HFNC use | 13 (21.7%) | 3 (20%) | 11 (22%) | 0.685 |
| O2 use days, median (IQR) | 3 (3–4) | 3(1–4) | 3(3–4) | 0.418 |
| Outcome measures | ||||
| -Total hospital stays, median (IQR) | 4 (3–5) | 4.5 (1.75–6.25) | 4 (3–5) | 0.738 |
| -Total PICU stays, median (IQR) | 2(2–3.25) | 5 | 3(2–3) | 0.144 |
| -Discharged, No (%) | 60 (100%) | 10 (100%) | 50 (100%) | – |
Abbreviations: SABA, Short-Acting Beta-2 Agonist; PICU, Pediatric Intensive Care Unit; HFNC, High Flow Nasal Cannula; O2, Oxygen; IQR, Interquartile Range.